Ironically knowledge of the curriculum of entrepreneurial revolution - as the net generation's opportunity to collaborate in human sustainability peaked in 1984 - unless you can help us retrieve it now - thans chris macrae wash dc text 240 316 8157 www.worldsocialtrade.com www.www.catholicuni.com amychina.net Anyone seriously transparent about affordable global health and sustainability needs to develop segments of health services and then decide whether an integrated service is still to have place boundaries. Understanding blockchain mapping is also absolutely essential:

online library of norman macrae--
egs ECONOMIES OF HEALTH:
infant and maternal health services can be the world's most social and economical- benchmark bangladesh villages
wellbeing and infectious disease prevention markets ought to be worldwide and very affordable the more openly connected worldwide youth can map
markets that involve surgery are always going to be as expesnive as health gets; markets depending on global pharma need a total different coonstitutiuon if they are ever to be economical
markets specialising in elderly depend on how a plavce's communities and family valuing structures are designed

Thursday, October 5, 2017

Guadalajara, Mexico | 11 – 14 October 2017
MSF EVENTS

endTB Symposium: Accelerating TB elimination through access to bedaquiline and delamanid Hall 10 - Jalisco Hall October 12 14:00 – 15:30
The symposium will provide an update on the UNITAID-funded endTB initiative and findings, including culture conversion and reversion and adverse events for the 600 people who have received bedaquiline or delamanid.
Community space (Encuentro) session: Five urgent improvements to DR-TB treatment Foro - Encuentro Expo October 13 17:00 – 18:00
Evidence for treatment with newer DR-TB drugs, shorter treatment regimens, ambulatory care instead of hospitisation, and fast-track registration of new drugs.
MSF Symposium: Reducing catastrophic costs for people with TB through patient-centred care Hall 10 - Jalisco Hall October 14 10:30 – 12:00
Session will analyse the barriers to reducing costs and burden for people with drug-resistant TB including: decentralised and ambulatory treater, shorter treatment and newer drugs to reduce toxicity, and interventions to reduce out-of-pocket costs of treatment.
ORAL ABSTRACTS

TB POLICIES
Many national TB programmes are out of step with international recommendations for testing, treatment and prevention: results of a 30 country survey Hall 2 – Events Ballroom October 12 16:00 – 17:30 SOA-365-12
Setting up an active pharmacovigilance system for the endTB project Hall 13 - Jalisco Hall October 13 10:30 – 12:00 OA-160-13
DRUG-RESISTANT TB TREATMENT
Early safety and efficacy of bedaquiline and delamanid combination for drug-resistant TB in Armenia, India and South Africa Plenary Hall October 13 10:30-12:00 OA-2905-13
Adverse events over 6 months with delamanid in a programmatic setting in Khayelitsha, South Africa Hall 13 – Jalisco Hall October 13 10:30 – 12:00 OA-162-13
Safety of multidrug resistant tuberculosis treatment amongst patients receiving bedaquiline in a compassionate use program in Armenia and Georgia Hall 13 – Jalisco Hall October 13 10:30 – 12:00 OA-163-13
Risk factors for developing hypothyroidism among MDR-TB patients receiving Eto and/or PAS in Maputo, Mozambique Hall 13 – Jalisco Hall October 13 10:30 – 12:00 OA-164-13
Psychiatric comorbidity among drug-resistant tuberculosis patients Hall 13 – Jalisco Hall October 13 10:30 – 12:00 OA-167-13
Culture conversion and reversion of multidrug resistant tuberculosis patients receiving bedaquiline in a compassionate use program in Armenia and Georgia Hall 13 – Jalisco Hall October 13 16:00 – 17:30 OA-188-13
Bedaquiline- and linezolid-based regimens for fluoroquinolone-resistant MDR-TB: how much better is it? Hall 13 – Jalisco Hall October 13 16:00 – 17:30 OA-190-13
Outcomes of multidrug resistant tuberculosis patients receiving Bedaquiline in a compassionate use program in Armenia and Georgia Hall 13 – Jalisco Hall October 13 16:00 – 17:30 OA-192-13
Delamanid for rifampicin-resistant tuberculosis: an observational cohort study from Khayelitsha, South Africa Hall 13 – Jalisco Hall October 13 16:00 – 17:30 OA-193-13
TB DIAGNOSTICS
Value of determine-TB LAM test as screening test and as diagnostic tool for tuberculosis diagnosis in HIV positive adults Hall 8 – Events Ballroom October 13 10:30 – 12:00 SOA-402-13
Cost-effectiveness of including determine TB-LAM test to diagnose tuberculosis in HIV-positive symptomatic patients Hall 4 – Events Ballroom October 14 10:30 – 12:00 SOA-443-14
LATENT TB INFECTION
Incidence of latent tuberculosis infection and tuberculosis disease after 24 months follow-up in paediatric contacts of drug-resistant tuberculosis patients in Armenia Hall 13 - Jalisco Hall October 12 14:00 – 15:30 SOA-360-12
CO-INFECTIONS (HCV)
High rates of active hepatitis C amongst multidrug resistant tuberculosis patients in Armenia Hall 14 - Jalisco Hall October 12 10:30 – 12:00 OA-125-12
POSTER PRESENTATIONS
All poster prentations take place in the Poster Area from 12:45 – 13:45 on the designated date

TB POLICIES
Threats to affordable quality second-line TB drugs in Eastern Europe/Central Asia as the Global Fund shifts to national procurement October 14 PD-893-14
DRUG-RESISTANT TB TREATMENT
Introduction of a short standardized course of treatment for multidrug-resistant Tuberculosis in Mozambique: cohort description and early culture conversion in HIV-positive and HIV-negative patients October 12 PD-537-12
Outcomes and risk factors in a program treating MDR-TB in Swaziland for 2011-2013 cohorts October 12 PD-547-12
Drug induced hypothyroidism during treatment for multidrug resistant tuberculosis in Swaziland October 13 PD-685-13
Lessons learned from the design, development, and deployment of endTB electronic medical record for MDR-TB across 16 countries October 13 PD-700-13
Interim report on the use of a short, simplified regimen for the treatment of children with multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan October 13 PD-809-13
Accelerating access to delamanid for rifampicin-resistant tuberculosis in Khayelitsha, South Africa October 14 PD-891-14
The impact of pyrazinamide resistance upon the treatment outcome of patients with multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan October 14 PD-894-14
TB DIAGNOSTICS
Evaluation of the OMNIgene® SPUTUM reagent for long term transportation of samples for Xpert testing in a high TB-HIV setting October 13 PD-837-13
Does the determine-TB LAM test have a potential value in tuberculosis diagnosis among severely acute malnourished (SAM) children? October 14 PD-924-14
LATENT TB INFECTION
Discordances between TST and IGRA to detect latent tuberculosis infection in paediatric contacts of drug-resistant tuberculosis patients October 14 PD-944-14
REPORTS
For MSF TB reports, go to: https://www.msfaccess.org/tb
· Out of Step 2017: www.msfaccess.org/outofstep2017
· DR-TB Drugs Under the Microscope, 5th Edition (COMING SOON)

No comments:

Post a Comment